about
Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysisSmall round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface moleculePlasma levels of soluble HLA-E and HLA-F at diagnosis may predict overall survival of neuroblastoma patientsIdentification of reference microRNAs and suitability of archived hemopoietic samples for robust microRNA expression profiling.Deregulation of focal adhesion pathway mediated by miR-659-3p is implicated in bone marrow infiltration of stage M neuroblastoma patients.Immunogenicity of human neuroblastoma.Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patientsPrognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastomaPD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillanceDetection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma.Low-dose interferon-gamma-producing human neuroblastoma cells show reduced proliferation and delayed tumorigenicity.Cloning and sequencing of isoform-specific regions of human Ca2+-independent protein kinase C (PKC)-encoding genes.Soluble HLA-G and HLA-E Levels in Bone Marrow Plasma Samples Are Related to Disease Stage in Neuroblastoma Patients.Evaluation of bone marrow as a metastatic site of human neuroblastoma.Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L.New immunotherapeutic strategies for the treatment of neuroblastoma.Neuroblastoma-derived TGF-β1 modulates the chemokine receptor repertoire of human resting NK cells.Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma.IL-10 and ARG-1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome.Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET.Bioavailability of antisense oligonucleotides in neuroblastoma cells: comparison of efficacy among different types of molecules.Induction of 2.5 OAS gene expression and activity is not sufficient for IFN-gamma-induced neuroblastoma cell differentiation.Protein kinase C isoenzymes in human neuroblasts. Involvement of PKC epsilon in cell differentiation.Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival.CD4+CD25hiCD127- Treg and CD4+CD45R0+CD49b+LAG3+ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma.Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma.Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity.Detection of cell-free RNA in children with neuroblastoma and comparison with that of whole blood cell RNA.Peripheral blood stem cell tumor cell contamination and survival of neuroblastoma patients.Restricted ROC curves are useful tools to evaluate the performance of tumour markers.Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction.Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: accuracy and relationship with clinical features of patients.Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen.Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages.Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis.Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials.Different subcellular localization of ALCAM molecules in neuroblastoma: Association with relapse.Seasonal variations of date of diagnosis and birth for neuroblastoma patients in ItalyMultiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors
P50
Q24562910-F790DEE8-C791-43D8-A252-9F6673925775Q24655582-053BCF58-8408-4AE5-A24C-74F65FDD33F3Q28304289-19A10217-45BF-48E6-B66A-5FCD6FC40A63Q34231622-B806C87E-A6B3-473D-8935-62A1A62230F4Q35955285-94DD4769-C666-44E3-B49D-BDCA0D2FD4DCQ36009145-84D6ED5A-82FF-46CF-871C-6454F85D5494Q36184329-E2D54EBD-DE00-4A2E-94D2-916A6E1BD4A2Q36446812-B1D3EF65-FC42-472D-8E72-B92132713F64Q36597354-D48B9C18-4314-42BF-9843-EAD99DB0F49BQ36614690-E92FB1F9-F77B-4363-96C6-EB06516B230DQ36694271-93909E15-2B1A-4003-A615-857F88AF9088Q36748034-4B37EEF5-9AC3-40CB-8342-C27AAEAB5827Q37215353-6F3C6533-63F7-442C-A374-77A6F3C09DE3Q38260230-491A60C7-5E96-41BC-8B68-6B118EB028D7Q38308633-CC72F6DC-C7A6-45C7-9AA8-3D0709034A1BQ38389316-2A097D22-F2DE-49E3-B519-F2D147D17AE8Q39168109-D6BE6103-7710-4100-8D4E-EF5A29411CE7Q40053162-018D281A-8763-4E62-AE52-CA763018CA84Q40190430-A2907A16-68CC-4D2F-B1FD-C201EC61E1D8Q40223249-2A9563AE-70C7-43FE-B533-F6B367F836AEQ41141056-523B3520-DDED-41C5-B138-91A1B0BD3EE8Q41325067-9DDC49FB-2D0A-4951-9FEF-E38D261029C6Q41553970-AB1BADF3-571F-431E-9152-BECF4540C8BDQ41579154-F70FD7F6-375A-49BA-B981-D92779AEBF8DQ42333778-21B03801-10AD-4138-B6FA-AA55C5310795Q42630498-6992483D-5588-4226-BC44-770B6FEAB83EQ42649288-FEF39A13-9B12-4DE3-B9B3-24805C1CBBD0Q43092516-B84EAF21-C09B-4DC3-A711-E76255F71A18Q43648240-3E2D3334-80E8-4D9D-843B-44D345D18E3EQ44436384-94112AE2-6233-420C-A2EF-CB4415BE7DA4Q44686821-FEA3A9E6-D6E9-4E9E-B39D-4070E9B75EDBQ45178477-5FCA7162-8F31-41AA-90CC-2191C6C9E029Q45875783-58DBE324-1AB8-4FD0-9D59-9285A576EFF4Q48136572-C8028D08-D00E-4564-96E9-A7AE6C81069DQ49085112-FD58A6EB-D7DB-4BCB-8DFB-94F25BF549B2Q52617490-7D53A686-BDA7-442F-9871-3B30F445BFDBQ52851055-B199D632-730C-4327-88D6-339D83BA3CC7Q53718880-CD8AA79A-08EA-4BC0-A5F1-98AB6DC22ECDQ54265672-3835DE61-FF54-41E0-92A1-6B6EAC8292A5Q54265705-53295B3E-D6D3-4EBD-98CE-19BBFBECE2DE
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Maria Valeria Corrias
@ast
Maria Valeria Corrias
@en
Maria Valeria Corrias
@es
Maria Valeria Corrias
@nl
Maria Valeria Corrias
@sl
type
label
Maria Valeria Corrias
@ast
Maria Valeria Corrias
@en
Maria Valeria Corrias
@es
Maria Valeria Corrias
@nl
Maria Valeria Corrias
@sl
prefLabel
Maria Valeria Corrias
@ast
Maria Valeria Corrias
@en
Maria Valeria Corrias
@es
Maria Valeria Corrias
@nl
Maria Valeria Corrias
@sl
P1053
E-4571-2011
P106
P21
P31
P3829
P496
0000-0002-7316-0772